Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Clinical, Cytogenetic and Immunophenotypic Spectra of Post-Transplant Relapse Following Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome

Elizabeth Kathryn Herrity, Tommy Alfaro, Mariana Pinto Pereira, Igor Novitzky-Basso, Wilson Lam, Ivan Pasic, Fotios Michelis, Arjun D. Law, Auro Viswabandya, Adam Smith, Anne Maria Tierens, Armin Gerbitz, Rajat Kumar, Jonas Mattsson, Dennis D. H. Kim

Blood (2023) 142 (Supplement 1): 2206.

https://doi.org/10.1182/blood-2023-187145

Published: 2023

Journal Articles

Real World Experience of FLT3-Inhibitor Post-Transplant Maintenance with Sorafenib Demonstrating Superior Overall- and Relapse Free Survival Following Allogeneic Hematopoietic Stem Cell Transplantation in FLT3-ITD Mutated Acute Myeloid Leukemia

Yomna Eissa, Eshrak Al-Shaibani, Igor Novitzky-Basso, Ivan Pasic, Wilson Lam, Jose-Mario Capo-chichi, Arjun D. Law, Fotios Michelis, Auro Viswabandya, Armin Gerbitz, Rajat Kumar, Jonas Mattsson, Dennis D. H. Kim

Blood (2023) 142 (Supplement 1): 3589.

https://doi.org/10.1182/blood-2023-185951

Published: 2023

Journal Articles

Use of Pre-Transplant Minicog Cognitive Impairment Screening and Validation of Frailty and Functionality Assessment Prior to Allogeneic Hematopoietic Stem Cell Transplantation

Tommy Alfaro, Maria Queralt Salas, Eshetu Atenafu, Ora Bascom, Leeann Wilson, Carol Chen, Arjun D. Law, Armin Gerbitz, Auro Viswabandya, Fotios Michelis, Jeffrey H. Lipton, Wilson Lam, Igor Novitzky-Basso, Dennis (Dong Hwan) Dong Hwan Kim, Jonas Mattsson, Ivan Pasic, Rajat Kumar

Blood (2023) 142 (Supplement 1): 5094.

https://doi.org/10.1182/blood-2023-191009

Published: 2023

Journal Articles

Outcomes of Allogeneic HSCT in Elderly Patients (70 years old and above) -a Canadian Experience

Yomna Eissa, Eshrak Al-Shaibani, Carol Chen, Shiyi Chen, Igor Novitzky-Basso, Arjun D. Law, Wilson Lam, Fotios Michelis, Auro Viswabandya, Armin Gerbitz, Ivan Pasic, Dennis D. H. Kim, Jeffrey H. Lipton, Jonas Mattsson, Rajat Kumar

Blood (2023) 142 (Supplement 1): 3733.

https://doi.org/10.1182/blood-2023-181118

Published: 2023

Journal Articles

Impact of Age on Hospitalization and Readmission on Post Allogeneic Stem Cell Transplantation Outcome, Single Center Experience

Eshrak Al-Shaibani, Shiyi Chen, Wilson Lam, Arjun Law, Ivan Pasic, Fotios Michelis, Auro Viswabandya, Dennis Dong Hwan Kim, Sr., Armin Gerbitz, Jeffrey H. Lipton, Jonas Mattson, Rajat Kumar

Blood (2021) 138 (Supplement 1): 4122.

https://doi.org/10.1182/blood-2021-146275

Published: 2021

Journal Articles

Propensity Score Matching Analysis Comparing Extracorporeal Photopheresis (ECP) Vs Best Available Therapy in Third Line or Later Treatment of Chronic Graft-Versus-Host Disease (cGVHD)

Swe Mar Linn, Igor Novitzky-Basso, Elizabeth Shin, Christopher J. Patriquin, Ivan Pasic, Wilson Lam, Arjun Law, Fotios Michelis, Armin Gerbitz, Auro Viswabandya, Jeffrey H. Lipton, Rajat Kumar, Jonas Mattsson, David Barth, Dennis Dong Hwan Kim, Sr.

Blood (2021) 138 (Supplement 1): 3896.

https://doi.org/10.1182/blood-2021-153045

Published: 2021

Journal Articles

ATG and Post-Transplant Cyclophosphamide Predisposes to Inferior Outcome When Using Cryopreserved Stem Cell Grafts

Igor Novitzky-Basso, Mats Remberger, Carol Chen, Ivan Pasic, Wilson Lam, Arjun Law, Armin Gerbitz, Auro Viswabandya, Jeffrey H. Lipton, Dennis Dong Hwan Kim, Rajat Kumar, Jonas Mattsson, Fotios Michelis

Blood (2021) 138 (Supplement 1): 479.

https://doi.org/10.1182/blood-2021-151744

Published: 2021

Journal Articles

Single Centre, Retrospective Analysis of Extracorporeal Photopheresis (ECP) Therapy in the Patients Who Are Heavily Pre-Treated for Steroid Resistant Chronic Graft-Versus-Host Disease (GVHD)

Swe Mar Linn, Igor Novitzky-Basso, Christopher J. Patriquin, Ivan Pasic, Wilson Lam, Arjun Law, Fotios Michelis, Armin Gerbitz, Auro Viswabandya, Jeffrey H. Lipton, Rajat Kumar, Jonas Mattsson, David Barth, Dennis Dong Hwan Kim, Sr.

Blood (2021) 138 (Supplement 1): 1806.

https://doi.org/10.1182/blood-2021-152640

Published: 2021

Journal Articles

Frailty Scale for Outcome Predictions in Hematopoietic Cell Transplanted Adults

Maria Queralt Salas, Eshetu G Atenafu, Eshrak Al-Shaibani, Ora Bascom, Leeann Wilson, Carol Chen, Ivan Pasic, Arjun Law, Wilson Lam, Dennis Dong Hwan Kim, Armin Gerbitz, Auro Viswabandya, Jeffrey H. Lipton, Fotios Michelis, Jonas Mattsson, Shabbir Alibhai, Rajat Kumar

Blood (2021) 138 (Supplement 1): 110.

https://doi.org/10.1182/blood-2021-153710

Published: 2021

Journal Articles

Donor Selection May Predict Improved Survival Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Chronic Myelomonocytic Leukemia - Experience from a Tertiary Care Centre

RAM V Nampoothiri, MDDM MRCP (UK), Carol Chen, Zeyad Al-Shaibani, MD, Ivan Pasic, MDPhD, Arjun Law, MD, Wilson Lam, MD, Fotios Michelis, MD PhD, Dennis Dong Hwan Kim, MD PhD, Armin Gerbitz, MDPhD, Auro Viswabandya, MD, Jeffrey H. Lipton, MD PhD, Jonas Mattsson, MD, Rajat Kumar, MD, Santhosh Thyagu, MDDM

Blood (2020) 136 (Supplement 1): 23–24.

https://doi.org/10.1182/blood-2020-142982

Published: 2020

Journal Articles

Single Centre, Retrospective Study to Evaluate Treatment Outcomes Following Tyrosine Kinase Inhibitor for Chronic Gvhd Treatment Including Ruxolitinib, Ibrutinib and Imatinib

Swe Mar Linn, MBBS, Omar Abduljalil, Igor Nicolas Novitzky-Basso, MDPhDMRCP,FRCPath, RAM V Nampoothiri, MDDM MRCP (UK), Ivan Pasic, MDPhD, Zeyad Al-Shaibani, MD, Wilson Lam, MD, Arjun Law, MD, Fotios Michelis, MD PhD, Armin Gerbitz, MDPhD, Auro Viswabandya, MD, Jeffrey H. Lipton, MD PhD, Rajat Kumar, MD, Jonas Mattson, MD PhD, Dennis Dong Hwan Kim, MD

Blood (2020) 136 (Supplement 1): 17–18.

https://doi.org/10.1182/blood-2020-142182

Published: 2020

Journal Articles

ATG and Post-Transplant Cyclophosphamide Do Not Abrogate the Inferior Outcome Risk Conferred By HLA-Α and HLA-B Mismatched Unrelated Donors

Igor Nicolas Novitzky-Basso, MDPhDMRCP,FRCPath, Remberger Mats, PhD, Carol Chen, Ivan Pasic, MDPhD, Zeyad Al-Shaibani, MD, Wilson Lam, MD, Arjun Law, MD, Armin Gerbitz, MDPhD, Auro Viswabandya, MDDM, Jeffrey H. Lipton, MD PhD, Dennis Dong Hwan Kim, MD PhD, Rajat Kumar, MD, Fotios Michelis, MD PhD, Jonas Mattsson, MD

Blood (2020) 136 (Supplement 1): 31.

https://doi.org/10.1182/blood-2020-139736

Published: 2020

Journal Articles

Efficacy and Cost Analysis of Eltrombopag in Thrombocytopenia and Poor Graft Function Post Allogeneic Hematopoietic Cell Transplantation in a Canadian Centre - a Prospective Observational Study

RAM V Nampoothiri, MDDM MRCP (UK), Lina Ho, Cassandra McEwan, Ivan Pasic, MDPhD, Zeyad Al-Shaibani, MD, Wilson Lam, MD, Arjun Law, MD, Fotios Michelis, MD PhD, Dennis Dong Hwan Kim, MD PhD, Armin Gerbitz, MDPhD, Auro Viswabandya, MD, Jeffrey H. Lipton, MD PhD, Jonas Mattsson, MD, Rajat Kumar, MD

Blood (2020) 136 (Supplement 1): 18.

https://doi.org/10.1182/blood-2020-142302

Published: 2020

Journal Articles

Allogeneic Transplant Can Abrogate the Relapse Risk in the Patients with Detectable Measureable Residual Disease By Multicolor Flow-Cytometry at the Time of Assessment of Acute Myeloid Leukemia Patients in First Remission

Muhned Alhumaid, MD, Georgina S. Daher-Reyes, MD, Arjun Law, MD, Auro Viswabandya, MD, Armin Gerbitz, MD, Fotios Michelis, MD PhD, Igor Nicolas Novitzky-Basso, MDPhDMRCP,FRCPath, Jeffrey H. Lipton, MD PhD, Jonas Mattson, MD PhD, Ivan Pasic, MDPhD, Rajat Kumar, MD, Wilson Lam, MD, Zeyad Al-Shaibani, MD, Hassan Sibai, MBBS, Dennis Dong Hwan Kim, MD

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-136122

Published: 2020

Journal Articles

Increased Risk of Secondary Malignancy Associated with the Use of Azathioprine for Chronic Graft-Versus-Host Disease Treatment

Igor Nicolas Novitzky-Basso, MDPhDMRCP,FRCPath, Ivan Pasic, MDPhD, Zeyad Al-Shaibani, MD, Wilson Lam, MD, Arjun Law, MD, Armin Gerbitz, MDPhD, Auro Viswabandya, MDDM, Jeffrey H. Lipton, MD PhD, Rajat Kumar, MD, Jonas Mattsson, MD, Fotios Michelis, MD PhD, Dennis Dong Hwan Kim, MD PhD

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-138927

Published: 2020

Journal Articles

Allogeneic Stem Cell Transplantation Has Limited Benefit in Older Patients with Mixed Phenotype Acute Leukemia

Blood (2019) 134 (Supplement_1): 5725.

https://doi.org/10.1182/blood-2019-129078

Published: 2019

NARROW

Clinical, Cytogenetic and Immunophenotypic Spectra of Post-Transplant Relapse Following Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome

Real World Experience of FLT3-Inhibitor Post-Transplant Maintenance with Sorafenib Demonstrating Superior Overall- and Relapse Free Survival Following Allogeneic Hematopoietic Stem Cell Transplantation in FLT3-ITD Mutated Acute Myeloid Leukemia

Use of Pre-Transplant Minicog Cognitive Impairment Screening and Validation of Frailty and Functionality Assessment Prior to Allogeneic Hematopoietic Stem Cell Transplantation

Outcomes of Allogeneic HSCT in Elderly Patients (70 years old and above) -a Canadian Experience

Impact of Age on Hospitalization and Readmission on Post Allogeneic Stem Cell Transplantation Outcome, Single Center Experience

Propensity Score Matching Analysis Comparing Extracorporeal Photopheresis (ECP) Vs Best Available Therapy in Third Line or Later Treatment of Chronic Graft-Versus-Host Disease (cGVHD)

ATG and Post-Transplant Cyclophosphamide Predisposes to Inferior Outcome When Using Cryopreserved Stem Cell Grafts

Single Centre, Retrospective Analysis of Extracorporeal Photopheresis (ECP) Therapy in the Patients Who Are Heavily Pre-Treated for Steroid Resistant Chronic Graft-Versus-Host Disease (GVHD)

Frailty Scale for Outcome Predictions in Hematopoietic Cell Transplanted Adults

Donor Selection May Predict Improved Survival Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Chronic Myelomonocytic Leukemia - Experience from a Tertiary Care Centre

Single Centre, Retrospective Study to Evaluate Treatment Outcomes Following Tyrosine Kinase Inhibitor for Chronic Gvhd Treatment Including Ruxolitinib, Ibrutinib and Imatinib

ATG and Post-Transplant Cyclophosphamide Do Not Abrogate the Inferior Outcome Risk Conferred By HLA-Α and HLA-B Mismatched Unrelated Donors

Efficacy and Cost Analysis of Eltrombopag in Thrombocytopenia and Poor Graft Function Post Allogeneic Hematopoietic Cell Transplantation in a Canadian Centre - a Prospective Observational Study

Allogeneic Transplant Can Abrogate the Relapse Risk in the Patients with Detectable Measureable Residual Disease By Multicolor Flow-Cytometry at the Time of Assessment of Acute Myeloid Leukemia Patients in First Remission

Increased Risk of Secondary Malignancy Associated with the Use of Azathioprine for Chronic Graft-Versus-Host Disease Treatment

Allogeneic Stem Cell Transplantation Has Limited Benefit in Older Patients with Mixed Phenotype Acute Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only